Nuevo escándalo de Novartis: ocultó graves efectos adversos del medicamento para la leucemia imatinib http://t.co/nZn6bQ7NmD #PtSafety
— Sano y salvo (@sanoysalvoblog) August 4, 2014
A proposed framework for Safety Measuring and Monitoring (BMJ Quality and Safety http://t.co/AQTvUvUSts pic.twitter.com/9IPsNdmqnU
— Alana Harper (@mini_dr) August 3, 2014
Sexo, sobornos y negocios en China. s/ el caso de GSK http://t.co/PUhi7wA1oA
— Martín Cañás (@mac_anas) August 4, 2014
Two papers in The BMJ with statin side effect errors shouldn’t be retracted, independent panel concludes http://t.co/8PQ9On0Uqr
— The BMJ (@bmj_latest) August 4, 2014
Se va animando la cosa para #polimedfest
http://t.co/ZcGayyl6t1
Cortos de calidad
Anímate, aún estás a tiempo!
Bases http://t.co/Cva81712z8
— Enrique Gavilán (@enriquegavilan) August 4, 2014
Two papers in The BMJ with statin side effect errors shouldn’t be retracted, independent panel concludes http://t.co/8PQ9On0Uqr
— The BMJ (@bmj_latest) August 4, 2014
Una reacción adversa a un medicamento administrado para tratar una reacción adversa(efecto cascada)http://t.co/vmsmxNErmt v @AEGRIS2 #SegPac
— Sano y salvo (@sanoysalvoblog) August 4, 2014
Patient Safety and Quality of Care Good Practices http://t.co/7asbteqiXL #SegPac #patientsafety #ptsafety
— carmen villar (@carmenvillarb) August 4, 2014
@sanoysalvoblog Imatinib (perderá la patente n 2015) y nilotinib (intentaban que substituyese al anterior), en leucemia mieloide crónica Ph+
— Juan Gérvas (@JuanGrvas) August 4, 2014
#PublicConsultation: Future #EU Agenda on quality of #healthcare: emphasis on #patientsafety. http://t.co/xeS8sCxNFi pic.twitter.com/vUzCfJcgcE
— EU_Health (@EU_Health) August 5, 2014
. @EU_Health opens consultation on quality of #healthcare with focus on #patientsafety. Have your say here: http://t.co/XUxL1YPi1J
— Interel EU Health (@Interel_Health) August 5, 2014
Emergency department triage: Reducing the risks at the front door @Sedgwick via @kimberlyanngeo http://t.co/YWcR73nD6V #PtSafety
— Sano y salvo (@sanoysalvoblog) August 5, 2014
Safety Issues at the End of Life in the Home Setting http://t.co/yBeMwyXRXp v @NursingCenter @EnferEvidente #PtSafety pic.twitter.com/U7JZo9HYbL
— Sano y salvo (@sanoysalvoblog) August 5, 2014
Tu relación con la industria farmacéutica puede perjudicar seriamente la salud de tus pacientes http://t.co/RzOwxUJQXc #SegPac
— Sano y salvo (@sanoysalvoblog) August 5, 2014
Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And Market Withdrawals http://t.co/ZWRrwPEVKD #PtSafety
— Sano y salvo (@sanoysalvoblog) August 5, 2014
Hope And Humility, by Peter J. Pronovost (Health_Affairs) http://t.co/MM6an4fkcJ #HealthCareQuality #PtSafety
— Sano y salvo (@sanoysalvoblog) August 5, 2014
SYSADOAS = placebo según GPC de calidad. No usar. Informe del servicio de evaluación vasco OSTEBA http://t.co/WgGN5brLgZ #Deprescripción
— Sano y salvo (@sanoysalvoblog) August 6, 2014
What's in a Name? World Health Organization issues proposal for biosimilar names.. read it here http://t.co/duyT5VHGwa #pharma #biotech
— pharmalot (@pharmalot) August 1, 2014
WHO INN Expert Group proposal: a system for assignment of Biological Qualifiers to similar biotherapeutic products http://t.co/xK4iiZ5OqH
— Sano y salvo (@sanoysalvoblog) August 6, 2014
The EMA is proposing they should be allowed to approve or censor all analyses of EU side effects data. WTF http://t.co/Aa74HXEGla #alltrials
— ben goldacre (@bengoldacre) August 6, 2014
The ‘systems approach’ to patient safety in healthcare: controversy and misconceptions (BMJ Q & S) http://t.co/5mgy6DaJa0 #PtSafety
— Sano y salvo (@sanoysalvoblog) August 8, 2014
Uso de pruebas cardiacas no indicadas en pacientes de bajo riesgo #ChoosingWisely http://t.co/aiEyI1QWsI Vía @BMJ_Qual_Saf
— Sano y salvo (@sanoysalvoblog) August 8, 2014
Electronic transmission of prescriptions, dispensing errors & prescription enhancements in English comm. pharmacies http://t.co/JgL1ykg2PX
— Sano y salvo (@sanoysalvoblog) August 8, 2014
La seguridad cardiovascular de la azitromicina (CMAJ) http://t.co/VTxfGNyrET #SegPac
— Sano y salvo (@sanoysalvoblog) August 8, 2014
Medición de la seguridad y seguimiento en atención sanitaria. Para equipos clínicos y org. sanitarias http://t.co/FzV8LuRBMo #SegPac
— Sano y salvo (@sanoysalvoblog) August 8, 2014
*El equipo que mantiene @sanoysalvoblog está compuesto por Cecilia Calvo Pita @cecilicp y Jesús Palacio Lapuente @je_pala.
Realiza la publicación de estas selecciones Txema Coll Benejam @txemacoll.
No hay comentarios:
Publicar un comentario